AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Rockwell Medical Inc. (RMTI)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.79

-0.06 (-3.24%)

At close: Feb 20, 2025, 3:59 PM

1.79

-0.28%

After-hours: Feb 20, 2025, 06:46 PM EST

undefined% (undefined)

Bid	1.76
Market Cap	58.01M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.04
PE Ratio (ttm)	-44.87
Forward PE	n/a
Analyst	Buy

Ask	1.83
Volume	154,556
Avg. Volume (20D)	427,074
Open	1.85
Previous Close	1.85
Day's Range	1.79 - 1.85
52-Week Range	1.23 - 5.15
Beta	undefined

About RMTI

Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stor...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Jan 27, 1998

Employees 237

Stock Exchange NASDAQ

Ticker Symbol RMTI

Website https://www.rockwellmed.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for RMTI stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 234.26% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Rockwell Medical Inc. is scheduled to release its earnings on Mar 20, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+10.45%

Rockwell Medical shares are trading higher after t... Unlock content with Pro Subscription

3 months ago

-39.14%

Rockwell Medical shares are trading lower. The company reported Q3 financial results.

News

19 hours ago · businesswire.com

Rockwell Medical to Release Fourth Quarter and Full-Year 2024 Results on Thursday, March 20, 2025

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the fourth quarter and full-year ended December 31, 2024 on Thursday, March 20, 2025.

2 weeks ago · businesswire.com

Rockwell Medical Adds Single-Use Bicarbonate Cartridge to Hemodialysis Concentrates Product Portfolio

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical adds a 510k approved single-use bicarbonate cartridge--in two sizes, 720g and 900g--to its hemodialysis concentrates po...

2 months ago · businesswire.com

Rockwell Medical Enters into a Multi-Year Product Purchase Agreement with the World's Leading Provider of Dialysis Products and Services

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical is the leading supplier of liquid bicarbonate in the United States.

2 months ago · businesswire.com

Rockwell Medical Promotes Jesse Neri to Chief Financial Officer

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Jesse Neri has been instrumental in strengthening Rockwell Medical's financial infrastructure and developing a stronger financial organi...

2 months ago · businesswire.com

Rockwell Medical Partners with HydroCare to Distribute and Install its Dry Acid Concentrate Mix System

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical's DAMX45 dry acid concentrate mix system is 510(k) approved to be used exclusively with the Company's dry acid concentr...